Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Chitayat syndrome is an ultrarare autosomal dominant disorder characterized by facial dysmorphism, hyperphalangism, respiratory compromise and variable skeletal anomalies. It is caused by heterozygous variants in ERF, a transcriptional repressor in the RAS/MAPK pathway, and defines a distinct clinical entity from ERF-related craniosynostosis and Noonan-like RASopathy.
A total of 13 unrelated individuals have been reported with the recurrent ERF c.266A>G (p.Tyr89Cys) variant: five patients in the initial cohort (3 de novo, 2 familial) ([PMID:27738187]), one case report ([PMID:30728880]), one patient ([PMID:30569521]) and six additional individuals ([PMID:32592542]). Paternal transmission in two families provides segregation evidence with two affected relatives.
The variant spectrum in Chitayat syndrome is dominated by the single missense change c.266A>G (p.Tyr89Cys) within the ETS DNA-binding domain; no other variant classes have been repeatedly associated with this phenotype.
Functional data specific to p.Tyr89Cys are not yet available, but its location in a highly conserved ETS domain predicts disrupted DNA binding and impaired repressor activity. No rescue or biochemical assays have been reported for this allele.
There is no conflicting evidence for p.Tyr89Cys in Chitayat syndrome; ERF loss-of-function variants cause overlapping but distinct RASopathy and craniosynostosis phenotypes.
In aggregate, the recurrent de novo and familial occurrences of c.266A>G (p.Tyr89Cys), consistent phenotype across 13 probands, and segregation in multiple families support a strong gene–disease association. Molecular testing for ERF c.266A>G enables definitive diagnosis and informed genetic counselling.
Gene–Disease AssociationStrong13 probands with recurrent c.266A>G (p.Tyr89Cys), multi-family segregation Genetic EvidenceStrong13 unrelated cases across four studies, including de novo and inherited AD missense variant Functional EvidenceLimitedNo direct functional assays for p.Tyr89Cys; predicted ETS-domain disruption |